Nurullah İlhan,MD· @drnurullahilhan · X·· 18 hours agoScore70
Body
FOURLIGHT-1: HR+/HER2− breast cancer after CDK4/6i.
Atirmociclib + fulvestrant met the phase II PFS endpoint:
9.4 vs 6.6 months; HR 0.60.
Control: fulvestrant OR everolimus/exemestane.
Separate superiority over the latter was not shown.
#FOURLIGHT1 #ESMO2026 #BCSM
8 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: Nurullah İlhan,MD · x.com